Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia

In conclusion, we report that DNA methylation profiles may vary even among CLL patients with similar somatic hypermutation status, supporting a compartmentalized approach to dissecting CLL biology. Furthermore, we highlight p63 as a novel prosurvival factor in CLL, thus identifying ano ther piece of the complex puzzle of clinical aggressiveness.This article is protected by copyright. All rights reserved.

Source: International Journal of Cancer - November 16, 2018 Category: Cancer & Oncology Authors: Nikos Papakonstantinou, Stavroula Ntoufa, Maria Tsagiopoulou, Theodoros Moysiadis, Sujata Bhoi, Andigoni Malousi, Fotis Psomopoulos, Larry Mansouri, Stamatia Laidou, Despoina Papazoglou, Maria Gounari, Konstantinos Pasentsis, Karla Plevova, V Tags: Research Article Source Type: research